Ftse Mib
34.405,17
0,09%
DAX
18.533,73
-0,36%
S&P 500
5.657,57
0,47%
NASDAQ
18.506,00
0,18%
Bitcoin
64.381,32
-0,73%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Blueprint Medicines Corporation (BPMC) Blueprint Medicines Corporation (BPMC) Notizie

BPMC

Blueprint Medicines (BPMC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BPMC
DataOraFonteTitoloSimboloCompagnia
06/08/201914:00PR Newswire (US)Blueprint Medicines to Present at 2019 Wedbush PacGrow Healthcare ConferenceNASDAQ:BPMCBlueprint Medicines Corporation
01/08/201922:21Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BPMCBlueprint Medicines Corporation
01/08/201913:32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BPMCBlueprint Medicines Corporation
01/08/201913:00PR Newswire (US)Blueprint Medicines Reports Second Quarter 2019 Financial ResultsNASDAQ:BPMCBlueprint Medicines Corporation
25/07/201914:00PR Newswire (US)Blueprint Medicines to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019NASDAQ:BPMCBlueprint Medicines Corporation
24/07/201900:23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BPMCBlueprint Medicines Corporation
18/07/201922:01PR Newswire (US)Blueprint Medicines Announces European Medicines Agency Validation of Marketing Authorization Application for Avapritinib for...NASDAQ:BPMCBlueprint Medicines Corporation
15/06/201912:00PR Newswire (US)Blueprint Medicines Presents Updated EXPLORER Trial Data for Avapritinib in Patients with Systemic Mastocytosis at 24th EHA C...NASDAQ:BPMCBlueprint Medicines Corporation
14/06/201914:45PR Newswire (US)Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PD...NASDAQ:BPMCBlueprint Medicines Corporation
03/06/201915:00PR Newswire (US)Blueprint Medicines' Highly Selective RET Inhibitor BLU-667 Shows Durable Anti-Tumor Activity in Patients with RET-Altered Ca...NASDAQ:BPMCBlueprint Medicines Corporation
01/06/201915:00PR Newswire (US)Blueprint Medicines Presents NAVIGATOR Trial Data in PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST at ASCO 2019 Supporting ...NASDAQ:BPMCBlueprint Medicines Corporation
29/05/201922:00PR Newswire (US)Blueprint Medicines to Present at Upcoming Investor Conferences in JuneNASDAQ:BPMCBlueprint Medicines Corporation
16/05/201915:00PR Newswire (US)Blueprint Medicines Announces Data Presentations at ASCO and EHA Meetings from Registration-Enabling Clinical Trials of Avapr...NASDAQ:BPMCBlueprint Medicines Corporation
09/05/201913:00PR Newswire (US)Blueprint Medicines Reports First Quarter 2019 Financial ResultsNASDAQ:BPMCBlueprint Medicines Corporation
08/05/201914:00PR Newswire (US)Blueprint Medicines to Present at Bank of America Merrill Lynch 2019 Health Care ConferenceNASDAQ:BPMCBlueprint Medicines Corporation
02/05/201914:00PR Newswire (US)Blueprint Medicines to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019NASDAQ:BPMCBlueprint Medicines Corporation
29/04/201922:26Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:BPMCBlueprint Medicines Corporation
29/04/201922:18Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:BPMCBlueprint Medicines Corporation
02/04/201922:01PR Newswire (US)Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common ...NASDAQ:BPMCBlueprint Medicines Corporation
29/03/201921:24Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:BPMCBlueprint Medicines Corporation
29/03/201901:40PR Newswire (US)Blueprint Medicines Announces Pricing of Public Offering of Shares of Common StockNASDAQ:BPMCBlueprint Medicines Corporation
27/03/201921:03PR Newswire (US)Blueprint Medicines Announces Proposed Public Offering of Shares of Common StockNASDAQ:BPMCBlueprint Medicines Corporation
27/03/201921:00PR Newswire (US)Blueprint Medicines Announces Accelerated Regulatory Submission Plans and Recent Clinical ProgressNASDAQ:BPMCBlueprint Medicines Corporation
18/03/201920:55Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:BPMCBlueprint Medicines Corporation
15/03/201921:16Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:BPMCBlueprint Medicines Corporation
05/03/201914:01PR Newswire (US)Blueprint Medicines to Present at 39th Annual Cowen & Co. Health Care ConferenceNASDAQ:BPMCBlueprint Medicines Corporation
26/02/201922:47Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:BPMCBlueprint Medicines Corporation
26/02/201922:41Edgar (US Regulatory)Annual Report (10-k)NASDAQ:BPMCBlueprint Medicines Corporation
26/02/201913:00PR Newswire (US)Blueprint Medicines Reports Fourth Quarter and Full Year 2018 Financial ResultsNASDAQ:BPMCBlueprint Medicines Corporation
19/02/201914:00PR Newswire (US)Blueprint Medicines to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019NASDAQ:BPMCBlueprint Medicines Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BPMC

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENI
Eni
BIT
ENEL
Enel
BIT
STLAM
Stellantis NV
BIT
FBK
Finecobank
BIT
RACE
Ferrari NV
BIT
PRY
Prysmian
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BC
Brunello Cucinelli
BIT
STMMI
ST Microelectronics
BIT
SPM
Saipem
BIT
BPE
Bper Banca
BIT
TEN
Tenaris
BIT
LDO
Leonardo
BIT
G
Generali
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network